Neuren Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NURPF research report →
Companywww.neurenpharma.com
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes.
- CEO
- Jonathan Charles Pilcher
- IPO
- 2009
- Employees
- 8
- HQ
- Camberwell, VIC, AU
Price Chart
Valuation
- Market Cap
- $1.12B
- P/E
- 54.26
- P/S
- 25.52
- P/B
- 4.88
- EV/EBITDA
- 74.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.93%
- Op Margin
- 11.03%
- Net Margin
- 47.09%
- ROE
- 9.20%
- ROIC
- 1.65%
Growth & Income
- Revenue
- $64.61M · -70.20%
- Net Income
- $30.42M · -78.58%
- EPS
- $0.24 · -77.98%
- Op Income
- $22.02M
- FCF YoY
- 1211.13%
Performance & Tape
- 52W High
- $14.80
- 52W Low
- $7.70
- 50D MA
- $8.57
- 200D MA
- $11.19
- Beta
- 1.56
- Avg Volume
- 78
Get TickerSpark's AI analysis on NURPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NURPF Coverage
We haven't published any research on NURPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NURPF Report →